About Rani Therapeutics
Rani Therapeutics is a company based in San Jose (United States) founded in 2012.. Rani Therapeutics has raised $234.14 million across 9 funding rounds from investors including Novartis, Astrazeneca and Takeda Pharmaceuticals. The company has 105 employees as of December 31, 2024. Rani Therapeutics offers products and services including RaniPill, RT-111, and RT-102. Rani Therapeutics operates in a competitive market with competitors including Aclaris Therapeutics, Adocia, BioAge Labs, Antag Therapeutics and Carmot, among others.
- Headquarter San Jose, United States
- Employees 105 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Rani Therapeutics Holdings, Inc.
-
Annual Revenue
$1.03 M0as on Dec 31, 2024
-
Net Profit
$-30.02 M11.63as on Dec 31, 2024
-
EBITDA
$-48.57 M25.59as on Dec 31, 2024
-
Total Equity Funding
$234.14 M (USD)
in 9 rounds
-
Latest Funding Round
$60.26 M (USD), Post-IPO
Oct 23, 2025
-
Investors
Novartis
& 14 more
-
Employee Count
105
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Rani Therapeutics
Rani Therapeutics is a publicly listed company on the NASDAQ with ticker symbol RANI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Rani Therapeutics
Rani Therapeutics offers a comprehensive portfolio of products and services, including RaniPill, RT-111, and RT-102. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Capsule for oral administration of biologics to improve patient compliance.
Platform for oral ustekinumab delivery in clinical trials.
System for repeated oral biologic dosing in therapeutic applications.
Unlock access to complete
Unlock access to complete
Funding Insights of Rani Therapeutics
Rani Therapeutics has successfully raised a total of $234.14M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $60.26 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Post-IPO — $60.3M
- First Round First Round
- Investors Count 15
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Post-IPO - Rani Therapeutics | Valuation |
investors |
|
| Dec, 2020 | Amount | Series E - Rani Therapeutics | Valuation |
investors |
|
| Nov, 2020 | Amount | Series E - Rani Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Rani Therapeutics
Rani Therapeutics has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Novartis, Astrazeneca and Takeda Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Corporate backed venture capital fund investing in multiple sectors
|
Founded Year | Domain | Location | |
|
Corporate-backed venture capital firm focused on retail tech, mobile tech, and multiple sectors
|
Founded Year | Domain | Location | |
|
Cathay Capital is engaged in global investment and transformation.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Rani Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Rani Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Rani Therapeutics Comparisons
Competitors of Rani Therapeutics
Rani Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Adocia, BioAge Labs, Antag Therapeutics and Carmot, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| domain | founded_year | HQ Location |
Bioinformatics platform is provided for biomarkers and drug discovery.
|
|
| domain | founded_year | HQ Location |
Peptide-based therapies for obesity and cardiometabolic disorders are developed.
|
|
| domain | founded_year | HQ Location |
Disease-modifying therapies for metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Endoscopic procedures for type-2 diabetes treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Rani Therapeutics
Frequently Asked Questions about Rani Therapeutics
When was Rani Therapeutics founded?
Rani Therapeutics was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Where is Rani Therapeutics located?
Rani Therapeutics is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
Who is the current CEO of Rani Therapeutics?
Talat Imran is the current CEO of Rani Therapeutics.
Is Rani Therapeutics a funded company?
Rani Therapeutics is a funded company, having raised a total of $234.14M across 9 funding rounds to date. The company's 1st funding round was a Series E of $50M, raised on Aug 28, 2013.
How many employees does Rani Therapeutics have?
As of Dec 31, 2024, the latest employee count at Rani Therapeutics is 105.
What is the annual revenue of Rani Therapeutics?
Annual revenue of Rani Therapeutics is $1.03M as on Dec 31, 2024.
What does Rani Therapeutics do?
Rani Therapeutics was founded in 2012 in San Jose, United States, within the biotechnology sector. A proprietary platform is utilized to enable oral delivery of biologics for chronic disease treatment. The RaniPill capsule is designed for applications in conditions such as acromegaly, rheumatoid arthritis, psoriatic arthritis, growth hormone deficiency, osteoporosis, Crohns disease, hemophilia, and diabetes. Operations focus on advancing this delivery technology for broader therapeutic use.
Who are the top competitors of Rani Therapeutics?
Rani Therapeutics's top competitors include Adocia, BioAge Labs and Fractyl.
What products or services does Rani Therapeutics offer?
Rani Therapeutics offers RaniPill, RT-111, and RT-102.
Is Rani Therapeutics publicly traded?
Yes, Rani Therapeutics is publicly traded on NASDAQ under the ticker symbol RANI.
Who are Rani Therapeutics's investors?
Rani Therapeutics has 15 investors. Key investors include Novartis, Astrazeneca, Takeda Pharmaceuticals, Cathay Financial Holdings, and Stevanato Group.
What is Rani Therapeutics's ticker symbol?
The ticker symbol of Rani Therapeutics is RANI on NASDAQ.